Asim Amin is an Oncology physician affiliated with Carolinas Healthcare System. OpenAlex indexes 127 publications with 7,312 citations (h-index 33).
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
1021 Morehead Medical Dr
Ste A
Charlotte, NC 282042990
Telephone
980-442-2000Registry record last updated 15 Jul 2024.
Industry payments
10 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Eisai Inc.Program year20253 payments
- Regeneron Pharmaceuticals, Inc.Program year20251 payment
- Merck Sharp & Dohme LLCProgram year20251 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cancer & immunology
37.5%Kinase inhibitor19.2%Lenvima73%Everolimus27%Part D<11 patientsB-Raf serine-threonine kinase (BRAF) inhibitors7.6%Braftovi100%Part D<11 patients+ 2 more classes in this area
Metabolism & gastrointestinal
25.6%Corticosteroid14.2%Prednisone100%Part D≥33 patientsProton pump inhibitor5.3%Pantoprazole Sodium100%Part D<11 patients+ 2 more classes in this area
Hormonal (systemic)
18.5%l-Thyroxine18.5%Levothyroxine Sodium100%Part D≥31 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Long-Term Progression-Free Survival of Patients with Metastatic Melanoma or Renal Cell Carcinoma following High-Dose Interleukin-2
Journal of Investigative Medicine
2021 - Neoadjuvant Nivolumab for Patients With Resectable Merkel Cell Carcinoma in the CheckMate 358 Trial
Journal of Clinical Oncology
2020
Similar KOLs
Other experts from the same institution or the same specialty.
Matthew McGirt, MD
Carolinas Healthcare System
Domagoj Coric, MD
Carolinas Healthcare System
Timothy Roush, MD
Carolinas Healthcare System
Donna Graves, MD
Carolinas Healthcare System
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”